165 related articles for article (PubMed ID: 35819628)
21. Comparison of Ultrasound Features With Maximum Standardized Uptake Value Assessed by 18F-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography for Prognosis of Estrogen Receptor+/Human Epithelial Growth Factor Receptor 2- Breast Cancer.
Choi B
Ultrasound Q; 2021 Nov; 38(1):18-24. PubMed ID: 35239627
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of FDG-PET and DWI in breast cancer.
Kitajima K; Miyoshi Y; Yamano T; Odawara S; Higuchi T; Yamakado K
Ann Nucl Med; 2018 Jan; 32(1):44-53. PubMed ID: 29134565
[TBL] [Abstract][Full Text] [Related]
23. The Predictive Value of Early Changes in
He M; Liu C; Shi Q; Sun Y; Zhang Y; Xu X; Yuan H; Zhang Y; Liu Y; Liu G; Di G; Yang Z; Wang Z; Shao Z
Oncologist; 2020 Nov; 25(11):927-936. PubMed ID: 32272493
[TBL] [Abstract][Full Text] [Related]
24. Role of
Akimoto E; Kadoya T; Kajitani K; Emi A; Shigematsu H; Ohara M; Masumoto N; Okada M
Clin Breast Cancer; 2018 Feb; 18(1):45-52. PubMed ID: 28993056
[TBL] [Abstract][Full Text] [Related]
25. Prediction of tumor differentiation using sequential PET/CT and MRI in patients with breast cancer.
Choi JH; Lim I; Noh WC; Kim HA; Seong MK; Jang S; Seol H; Moon H; Byun BH; Kim BI; Choi CW; Lim SM
Ann Nucl Med; 2018 Jul; 32(6):389-397. PubMed ID: 29797002
[TBL] [Abstract][Full Text] [Related]
26. Complete Metabolic Response on Interim
Chen S; Ibrahim NK; Yan Y; Wong ST; Wang H; Wong FC
Oncologist; 2017 May; 22(5):526-534. PubMed ID: 28377466
[TBL] [Abstract][Full Text] [Related]
27. Association between Oncotype DX recurrence score and dynamic contrast-enhanced MRI features in patients with estrogen receptor-positive HER2-negative invasive breast cancer.
Kim HJ; Choi WJ; Kim HH; Cha JH; Shin HJ; Chae EY
Clin Imaging; 2021 Jul; 75():131-137. PubMed ID: 33548871
[TBL] [Abstract][Full Text] [Related]
28. Diffusion-weighted imaging and (18) F-fluorodeoxyglucose positron emission tomography/computed tomography in breast cancer: Correlation of the apparent diffusion coefficient and maximum standardized uptake values with prognostic factors.
Karan B; Pourbagher A; Torun N
J Magn Reson Imaging; 2016 Jun; 43(6):1434-44. PubMed ID: 26663655
[TBL] [Abstract][Full Text] [Related]
29. PIK3CA Mutational Status Is Associated with High Glycolytic Activity in ER+/HER2- Early Invasive Breast Cancer: a Molecular Imaging Study Using [
Magometschnigg H; Pinker K; Helbich T; Brandstetter A; Rudas M; Nakuz T; Baltzer P; Wadsak W; Hacker M; Weber M; Dubsky P; Filipits M
Mol Imaging Biol; 2019 Oct; 21(5):991-1002. PubMed ID: 30652258
[TBL] [Abstract][Full Text] [Related]
30. 18F-FDG uptake by metastatic axillary lymph nodes on pretreatment PET/CT as a prognostic factor for recurrence in patients with invasive ductal breast cancer.
Song BI; Lee SW; Jeong SY; Chae YS; Lee WK; Ahn BC; Lee J
J Nucl Med; 2012 Sep; 53(9):1337-44. PubMed ID: 22870824
[TBL] [Abstract][Full Text] [Related]
31. Early Metabolic Response to Neoadjuvant Treatment: FDG PET/CT Criteria according to Breast Cancer Subtype.
Groheux D; Majdoub M; Sanna A; de Cremoux P; Hindié E; Giacchetti S; Martineau A; de Roquancourt A; Merlet P; Visvikis D; Resche-Rigon M; Hatt M; Espié M
Radiology; 2015 Nov; 277(2):358-71. PubMed ID: 25915099
[TBL] [Abstract][Full Text] [Related]
32. A multiparametric [
Leithner D; Horvat JV; Bernard-Davila B; Helbich TH; Ochoa-Albiztegui RE; Martinez DF; Zhang M; Thakur SB; Wengert GJ; Staudenherz A; Jochelson MS; Morris EA; Baltzer PAT; Clauser P; Kapetas P; Pinker K
Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1878-1888. PubMed ID: 31197455
[TBL] [Abstract][Full Text] [Related]
33. Associations between the standardized uptake value of (18)F-FDG PET/CT and the prognostic factors of invasive lobular carcinoma: in comparison with invasive ductal carcinoma.
Jung NY; Kim SH; Choi BB; Kim SH; Sung MS
World J Surg Oncol; 2015 Mar; 13():113. PubMed ID: 25889560
[TBL] [Abstract][Full Text] [Related]
34. Percentage change of primary tumor on 18F-FDG PET/CT as a prognostic factor for invasive ductal breast cancer with axillary lymph node metastasis: Comparison with MRI.
Yoo J; Kim BS; Chung J; Yoon HJ
Medicine (Baltimore); 2017 Aug; 96(31):e7657. PubMed ID: 28767583
[TBL] [Abstract][Full Text] [Related]
35. Metabolic activity of breast cancer metastatic lesions on positron emission tomography/computed tomography: comparison with histological and biological characteristics of primary tumor.
Sobic Saranovic D; Stojiljkovic M; Susnjar S; Odalovic S; Artiko V; Pavlovic S; Grozdic-Milojevic I; Obradovic V
Neoplasma; 2016; 63(2):313-21. PubMed ID: 26774154
[TBL] [Abstract][Full Text] [Related]
36. Comparison of standardized uptake value of 18F-FDG-PET-CT with 21-gene recurrence score in estrogen receptor-positive, HER2-negative breast cancer.
Ahn SG; Lee JH; Lee HW; Jeon TJ; Ryu YH; Kim KM; Sohn J; Yun M; Lee SA; Jeong J; Kim SI
PLoS One; 2017; 12(4):e0175048. PubMed ID: 28419166
[TBL] [Abstract][Full Text] [Related]
37. Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer.
Ueda S; Tsuda H; Asakawa H; Shigekawa T; Fukatsu K; Kondo N; Yamamoto M; Hama Y; Tamura K; Ishida J; Abe Y; Mochizuki H
Jpn J Clin Oncol; 2008 Apr; 38(4):250-8. PubMed ID: 18407934
[TBL] [Abstract][Full Text] [Related]
38. In ER-Positive, HER2-Negative Breast Cancers, HER2 mRNA Levels Correlate Better with Clinicopathologic Features and Oncotype DX Recurrence Score than HER2 Immunohistochemistry.
Tyburski H; Karakas C; Finkelman BS; Turner BM; Zhang H; Hicks DG
Lab Invest; 2024 Mar; 104(3):100309. PubMed ID: 38135156
[TBL] [Abstract][Full Text] [Related]
39. Convolutional Neural Network Using a Breast MRI Tumor Dataset Can Predict Oncotype Dx Recurrence Score.
Ha R; Chang P; Mutasa S; Karcich J; Goodman S; Blum E; Kalinsky K; Liu MZ; Jambawalikar S
J Magn Reson Imaging; 2019 Feb; 49(2):518-524. PubMed ID: 30129697
[TBL] [Abstract][Full Text] [Related]
40. Journal Club: Diagnostic value of (18)F-FDG PET/CT and MRI in predicting the clinicopathologic subtypes of invasive breast cancer.
Miyake KK; Nakamoto Y; Kanao S; Tanaka S; Sugie T; Mikami Y; Toi M; Togashi K
AJR Am J Roentgenol; 2014 Aug; 203(2):272-9. PubMed ID: 25055259
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
